Session Information
2008 Summer Meeting
Reduction in intravenous immunoglobulin (IVIG or Anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving romiplostim (AMG 531) in two, phase III, randomized, placebo-controlled trials
Track: Abstracts
Program Code:P61E
Date: 10 June 2008
Time: Tuesday, June 10, 2008
PRIMARY AUTHOR:
Todd Gadberry
AUTHOR(S):
Mark Nelson, Director, Pharmaceutical Svcs & Clinical Research, Northwest Medical Specialties, PLLC
Alfred Chin
Scott Drugan
John Isitt